XOMA Collaboration with Arana Therapeutics

XOMA Ltd. (Nasdaq:XOMA) and Arana Therapeutics Limited, a wholly-owned subsidiary of Cephalon, Inc. (Nasdaq:CEPH) will collaborate on multiple proprietary XOMA antibody R&D technologies, including a new antibody phage display library, and a suite of integrated information and data management systems. Arana will pay XOMA a fee of $6 million and XOMA will receive milestone payments and royalties on product sales. The proprietary antibody library covered by the collaboration is one of a series of proprietary antibody libraries being developed by XOMA scientists to overcome existing limitations in library design by combining “best-in-class” techniques with XOMA’s own proprietary and patent-protected technologies. Access to multiple libraries may offer benefits to XOMA and its partners because it enables the use of libraries best suited to the needs of a particular discovery project.